Polymyxin B

Summary

Polymyxin B (CHEMBL5314354) is an approved protein (ATC J01XB02) targeting P2RX7; indicated across 6 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: J01XB02 (+4 more)
• Targets: 1 (P2RX7)
• Indications: 6 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314354
Name	Polymyxin B
Type	Protein
Max phase	4
ATC	J01XB02, S02AA11, A07AA05, S03AA03, S01AA18

Also known as: Polimixina b, Polymixin b, Polymyxin b, Polymyxin b component of polysporin, Polymyxine b, Polymyxin, PMB, Polymyxin B (PMB), Polymyxin B, polymyxin B, polymyxin B sulphate, polymixin B

Parent form; salt/anhydrous children: CHEMBL5314355

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
P2RX7	P2X7	Positive		1.7%	Q99572

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Toll-like receptor 4.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TLR4	5.91	IC50	1230	nM	CHEMBL_ACT_1688982

Target pathways

Aggregated over 1 target gene(s): P2RX7.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Elevation of cytosolic Ca2+ levels	1	P2RX7
Platelet homeostasis	1	P2RX7
The NLRP3 inflammasome	1	P2RX7
Purinergic signaling in leishmaniasis infection	1	P2RX7
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	1	P2RX7

Dominant GO biological processes

GO term	Targets
MAPK cascade	1
cell morphogenesis	1
phagolysosome assembly	1
T cell mediated cytotoxicity	1
positive regulation of T cell mediated cytotoxicity	1
regulation of sodium ion transport	1
response to ischemia	1
membrane protein ectodomain proteolysis	1
phospholipid transfer to membrane	1
vesicle budding from membrane	1
inflammatory response	1
mitochondrion organization	1
cell surface receptor signaling pathway	1
protein secretion	1
response to xenobiotic stimulus	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
graft versus host disease	2	MONDO:0013730	EFO:0004599
pneumonia	2	MONDO:0005249	EFO:0003106

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	3
Not specified	3
PHASE4	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07004049	PHASE4	RECRUITING	Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT02328183	PHASE4	UNKNOWN	Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria
NCT07326540	PHASE3	RECRUITING	Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
NCT01429701	PHASE3	COMPLETED	Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
NCT02134106	PHASE2/PHASE3	WITHDRAWN	Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
NCT03159078	PHASE3	UNKNOWN	Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
NCT03920007	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
NCT07580586	PHASE1	RECRUITING	A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
NCT05063422	PHASE1	COMPLETED	Retentive Strength of Denture Adhesives on Various RR Ridges
NCT05359627	PHASE1	COMPLETED	A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency
NCT03950544	EARLY_PHASE1	UNKNOWN	The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
NCT06595979	Not specified	RECRUITING	Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB
NCT07495150	Not specified	NOT_YET_RECRUITING	Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
NCT07549828	Not specified	NOT_YET_RECRUITING	Sebum Metabolomics and Lipidomics for Clinical Applications

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

8 molecules share ≥1 primary target. Top 8 by shared-target count:

Molecule	Source	Status	Shared targets
BRILLIANT BLUE G	ChEMBL	Phase 4 (approved)	P2RX7
SURAMIN	ChEMBL	Phase 3	P2RX7
AZD9056	ChEMBL	Phase 2	P2RX7
CE-224535	ChEMBL	Phase 2	P2RX7
JNJ-54175446	ChEMBL	Phase 2	P2RX7
OXATOMIDE	ChEMBL	Phase 2	P2RX7
ZANVIPIXANT	ChEMBL	Phase 2	P2RX7
Berberine Chloride	PubChem	Approved	P2RX7